Sells AUCATZYL, an engineered T-cell treatment for adults with a type of blood cancer, and develops other T-cell treatments for cancer and autoimmune diseases.
10-K for FY2025, filed Mar 27, 2026We are an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and…View ↗
AUCATZYL is a B-lymphocyte antigen CD19 (“CD19”) chimeric antigen receptor (“CAR”) T cell therapy. AUCATZYL is designed with a fast target…View ↗
Obe-cel is also being developed for the treatment of autoimmune indications, and we have initiated a Phase 1 trial in patients with severe…View ↗
Cardinal Health pays for AUCATZYL after delivery and acceptance at a treatment center. License agreements can bring upfront fees, milestone payments and royalties on licensed-product sales.
10-K for FY2025, filed Mar 27, 2026As of December 31, 2025, the Company's product revenue has solely been comprised of sales of AUCATZYL in the U.S. The Company uses Cardinal…View ↗
The Company accounts for its revenues pursuant to the provisions of ASC 606. The Company entered into various license agreements which…View ↗
The Company is eligible to receive milestone payments of up to $32.0 million in the aggregate upon the achievement of specified clinical…View ↗
$75.4M
10-K for FY2025, filed Mar 27, 2026
$75.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2025, filed Mar 27, 2026 |
99% |
Product revenue, net, FY2025
$74.3M Sources
|
Sold outright |
|
License
Licensed
|
1.5%
FY2022: 97%
|
License, FY2025
$1.1M Sources
|
Licensed |
Patients are the customers for AUCATZYL; Cardinal Health delivers it to authorized treatment centers. License revenue came primarily from Moderna.
10-K for FY2025, filed Mar 27, 2026As of December 31, 2025, the Company's product revenue has solely been comprised of sales of AUCATZYL in the U.S. The Company uses Cardinal…View ↗
The Company has determined that the patient is the customer in the arrangement pursuant to ASC 606. The Company has identified a single…View ↗
The Company recognized license revenue of $1.1 million during the year ended December 31, 2025, primarily from Moderna. During the year…View ↗
No. It lost $287.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
Open tableView ↗
8-K, filed Nov 10, 2026
If the title goes over more than one line move the subtitle text box down by 1.15cm per additional line Executing to the commercial plan in…View ↗
8-K, filed Aug 3, 2026
On August 3, 2026, the Company announced an increase in full year 2026 guidance for AUCATZYL® net product revenue to $140 million to $150…View ↗
8-K, filed Apr 16, 2026
On April 14, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Autolus Therapeutics plc (the “Company”)…View ↗
Growing. Revenue grew 32.4x in 4 years, from $2.3M in FY2021 to $75.4M in FY2025, about 138% a year.
From development to sales
The older report described obe-cel as investigational; the latest describes AUCATZYL as approved and sold in the United States, with a United Kingdom launch.
20-F for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 27, 2026Obe-cel (obecabtagene autoleucel) is a CD19-targeting programmed T cell investigational therapy with a CD19 binder designed to improve the…View ↗
Broader disease focus
Autoimmune disease has joined cancer as a development focus: the older report framed its T-cell programs around cancer, while the latest also discusses obe-cel development for lupus and multiple sclerosis.
20-F for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 27, 2026We are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using our broad…View ↗
Obe-cel is also being developed for the treatment of autoimmune indications, and we have initiated a Phase 1 trial in patients with severe…View ↗
Competes with Amgen, Bristol Myers Squibb, Novartis, Janssen Biotech, Kite, Cabaletta, Kyverna, and Cartesian
10-K for FY2025, filed Mar 27, 2026More recently, redirected T cell therapies that are designed to give the patient’s T cells a new specificity to recognize cancer cells have…View ↗
Loading...